Braun Stacey Associates’s Ascendis Pharma A/S ASND Stock Holding History

Braun Stacey Associates’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.4M	Buy	132,682 +1,690	+1%	+$395K	1%	32
2026 Q1	$30M	Buy	130,992 +11,897	+10%	+$2.67M	1%	35
2025 Q4	$25.4M	Buy	119,095 +25,148	+27%	+$5.19M	0.82%	47
2025 Q3	$18.7M	Buy	+93,947	New	+$17.5M	0.61%	74

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Braun Stacey Associates's ASND Position: Q2 2026 in Review

Braun Stacey Associates increased its Ascendis Pharma A/S (ASND) stake by 1.3% in Q2 2026, buying an estimated $395K and bringing the position to 132,682 shares worth $35.4M. The position accounts for 1% of the portfolio, ranked #32.

Braun Stacey Associates first reported a position in ASND in Q3 2025 and has held it in 4 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Braun Stacey Associates held 132,682 shares of Ascendis Pharma A/S worth $35.4M as of Q2 2026.
Braun Stacey Associates bought 1,690 Ascendis Pharma A/S shares in Q2 2026, an estimated $395K.
Ascendis Pharma A/S made up 1% of Braun Stacey Associates's portfolio in Q2 2026, its #32 holding.
Braun Stacey Associates first reported a position in Ascendis Pharma A/S in Q3 2025 and has held it in 4 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Braun Stacey Associates's 13F filing for Q2 2026, filed 5 Aug 2026.